General Information

Agenda

Brief Update

Meeting Report

Scribes

• Session 1
• Session 2
• Session 3
• Session 4
• Session 5
• Session 6
• Session 7

List of Participants

Photo Gallery

Feedback & Evaluation

Session 1 Introductions, objectives, key updates

Introduction and overview of agenda and objectives Olugbenga Mokuolu & Noella Umulisa, CMWG

Opening Remarks

• Daniel Ngamije, WHO, Global Malaria Programme
• Michael Charles, CEO, RBM Partnership to End Malaria
• Claude Mambo Muvunyi, Director General, Rwanda Biomedical Center

Progress towards malaria elimination in Rwanda Aimable Mbituyumuremyi, National Malaria Control Program, Rwanda

Technical updates on malaria case management from the WHO Global Malaria Programme Peter Olumese, WHO GMP

Update from RBM Partnership to End Malaria Daddi Wayessa, RBM Partnership to End Malaria

Discussion on the RBM CMWG objectives, core team, membership, activities, expectations from members Noella Umulisa  & Konstantina Boutsika, CMWG

Session 2 Antimalarial drug resistance

Global status and containment measures for antimalarial drug resistance Charlotte Rasmussen, WHO GMP

Multiple First-line (MFT) for malaria: concept and updates Bernhards Ogutu, KEMRI

MFT country experience: Kenya Andrew Cole, Strathmore University, Kenya

Updates of DeTACT Africa: A trial to compare the efficacy, safety, tolerability of combinations of 3 Anti-malarial drugs against combinations of 2 Antimalarial drugs (DeTACT Africa) Updates Mehul Dhorda, Mahidol-Oxford Tropical Medicine, UK

East Africa's regional effort to tackle antimalarial resistance Karen Barnes,University of Cape Town, South Africa

Update/status of ganaplacide/lumefantrine SDF for acute uncomplicated malaria Caroline Boulton, Novartis

TES updates: barriers and opportunities and Q&A Peter Olumese & Charlotte Rasmussen, WHO GMP

Session 4 Severe Malaria

Status of severe malaria – Country experiences and best practices: Country Programmes

• Digitization  Directorate (Rwanda)
• Anitta Kamara (Sierra Leone)
• Nnenna Ogbulafor (Nigeria)
• Doudou Sene (Senegal)

Quality of care and referrals to support the journey of severe malaria patients Jean Okitawutshu, DRC

An update on the new 1-step injectable artesunate Cyrus Baidoo, Guilin Pharma

The challenge of misuse of injectable artesunate in non-severe malaria patients Jimmy Opigo, NMCP Uganda

Update on KARISMA study with Cipargamin Caroline Boulton, Novartis

Early findings from the SEMA ReACT project in DRC and Zambia Hypolite Muhindo, DRC

Where can rectal artesunate save lives? Summary of the most recent contributions in the scientific literature James Watson, Infectious Diseases Data Observatory, University of Oxford, UK

Session 5 Malaria Quality of care: Diagnosis

Update on Malaria Diagnosis: Successes and Challenges Anderson Chinorumba, WHO GMP

Updates on the Community of Practice (CoP) on pfhrp2/3 gene deletions Deus Ishengoma, NIMR, Tanzania & MESA

New malaria diagnostic tools Luis Gonzalez, Abbott Rapid Diagnostics

Total Quality Management for malaria  microscopy Anderson Chinorumba, WHO GMP

Session 6 Quality improvement of malaria case management

Malaria QI approaches in Mozambique (non OTSS+) Mércia Dabo-Dimene, NMCP Mozambique

Malaria QI approaches in Mali (OTSS+) Aissata Kone, NMCP Mali

Presentation of OTSS Manual Nicole Whitehurst, PATH & Peter Troell, PMI

Brief updates from other RBM Working Groups

• Molly Robertson, SMEWG
• Simret Habtezgi, MIPWG

Session 7 Vaccines and other chemoprevention tools

WHO update on malaria vaccines and other chemoprevention tools Dorothy Achu & Adidja Amani, WHO AFRO

Wrap up